ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and ...

Eli Lilly drops a second Phase III readout for orforglipron; AbbVie committed to the psychedelic therapeutics space with the ...

Eli Lilly & Company LLY and Pfizer PFE are both large-cap U.S. pharmaceutical giants with diversified drug portfolios and ...

Eli Lilly’s investigational obesity pill helped lower weight and blood sugar in patients with obesity and type 2 diabetes.

Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its ...

The Asia–Pacific region has a high global burden of cardiovascular disease.1 The region, home to more than 60% of the world's population, spans the vast and diverse geographies from Oceania through ...

The drug, based on Nobel Prize-winning gene-editing technology CRISPR-Cas9, reaches the liver cells and splices out the ...

In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing ...

For savvy investors looking for long-term businesses that not only dominate their industries today but also have the ...

Eli Lilly and Company’s LLY stock has declined 5.1% so far this month, despite announcing strong second-quarter results on ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...